IN183539B - - Google Patents

Info

Publication number
IN183539B
IN183539B IN26CA1998A IN183539B IN 183539 B IN183539 B IN 183539B IN 26CA1998 A IN26CA1998 A IN 26CA1998A IN 183539 B IN183539 B IN 183539B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Steven Carl Quay
Panayiotis Peri Constantinides
Karel Jay Lambert
Original Assignee
Sonus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sonus Pharma Inc filed Critical Sonus Pharma Inc
Publication of IN183539B publication Critical patent/IN183539B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN26CA1998 1997-01-07 1998-01-06 IN183539B (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3418897P 1997-01-07 1997-01-07
US4884097P 1997-06-06 1997-06-06
US09/003,173 US6458373B1 (en) 1997-01-07 1998-01-05 Emulsion vehicle for poorly soluble drugs

Publications (1)

Publication Number Publication Date
IN183539B true IN183539B (de) 2000-02-05

Family

ID=27357338

Family Applications (1)

Application Number Title Priority Date Filing Date
IN26CA1998 IN183539B (de) 1997-01-07 1998-01-06

Country Status (15)

Country Link
US (10) US6458373B1 (de)
EP (1) EP0981328B1 (de)
JP (2) JP2001508445A (de)
KR (1) KR100612528B1 (de)
AR (1) AR011518A1 (de)
AT (1) ATE356611T1 (de)
CA (1) CA2276730C (de)
DE (1) DE69837328T2 (de)
DK (1) DK0981328T3 (de)
ES (1) ES2285753T3 (de)
IL (1) IL130737A0 (de)
IN (1) IN183539B (de)
PT (1) PT981328E (de)
TW (2) TW579297B (de)
WO (1) WO1998030205A1 (de)

Families Citing this family (359)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US20030059465A1 (en) * 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
EP1117384A1 (de) * 1998-10-01 2001-07-25 Elan Pharma International Limited Nanopartikelformulierungen mit kontrollierter wirkstofffreisetzung
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
PL348193A1 (en) * 1998-12-11 2002-05-06 Pharmasolutions Self-emulsifying compositions for drugs poorly soluble in water
WO2000059488A2 (en) * 1999-04-02 2000-10-12 Washington State University Research Foundation Enhanced tissue and subcellular delivery of vitamin e compounds
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
HUP0203903A3 (en) * 1999-04-13 2004-09-28 Leo Pharm Prod Ltd Solubilized pharmaceutical composition for parenteral administration and its use
KR20070058028A (ko) * 1999-05-24 2007-06-07 소너스파머슈티칼즈인코포레이티드 난용성 약물용 에멀젼 부형제
KR100754352B1 (ko) * 1999-05-24 2007-08-31 소너스파머슈티칼즈인코포레이티드 난용성 약물용 에멀젼 부형제의 제조방법
EP1479382A1 (de) * 1999-06-18 2004-11-24 IVAX Research, Inc. Taxane enthaltende orale Pharmazeutische Zusammensetzungen sowie Behandlungsverfahren unter deren Verwendung
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
JP2003513019A (ja) 1999-09-27 2003-04-08 ソーナス ファーマシューティカルス，インコーポレイテッド トコール可溶性治療剤の組成物
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
AU2001225432A1 (en) * 2000-01-20 2001-07-31 Supratek Pharma, Inc. Novel podophyllotoxin compositions
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
GB0016876D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
EP1303261B1 (de) * 2000-07-24 2005-03-09 Pharmacia & Upjohn Company Selbstemulgierendes system zur abgabe von sehr wasserunlöslichen und lipophilen arzneimitteln
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
AU2001293177A1 (en) * 2000-09-27 2002-04-08 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE60140141D1 (de) * 2000-11-14 2009-11-19 Vital Health Sciences Pty Ltd Zusammensetzungen umfassend Komplexe von Tocopherolphosphatderivaten
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
ATE316786T1 (de) * 2000-11-22 2006-02-15 Rxkinetix Inc Behandlung von mukositis
JP2004536026A (ja) * 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
EP1345589B1 (de) * 2000-11-29 2007-06-27 Lyotropic Therapeutics, Inc. Lösungsmittelsysteme für pharmazeutische mittel
DE60136648D1 (de) * 2000-12-05 2009-01-02 Los Angeles Childrens Hospital Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung
IN188917B (de) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1420797A4 (de) 2001-07-27 2005-03-02 Vital Health Sciences Pty Ltd Hauttherapie unter verwendung von phosphatderivaten von elektronentransfermitteln
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
US20030099674A1 (en) * 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US6858227B1 (en) 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US20030191093A1 (en) * 2001-12-03 2003-10-09 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060078618A1 (en) * 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
DE60238276D1 (de) * 2001-12-13 2010-12-23 Vital Health Sciences Pty Ltd Transdermaler transport von verbindungen
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US6683194B2 (en) * 2002-02-05 2004-01-27 Sonus Pharmaceuticals, Inc. Tocopherol derivatives
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
JP2005524657A (ja) * 2002-02-27 2005-08-18 ファーメイン， エルティーディー． 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
JP2005523295A (ja) * 2002-03-01 2005-08-04 ノバガリ、ファルマ、エスアー 難溶性薬剤の自己乳化型薬物送達システム
EP1340497A1 (de) * 2002-03-01 2003-09-03 Novagali Sas Selbstemulgierende Systeme zur Abgabe von schwerlöslichen Arzneimitteln
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
NZ536308A (en) 2002-05-24 2009-01-31 Angiotech Int Ag Compositions and methods for coating medical implants
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
BR0313024A (pt) 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
ES2336911T3 (es) 2002-11-07 2010-04-19 Kosan Biosciences, Inc. Trans-9,10-dehidroepotilonas c y d, sus analogos y procedimientos de preparacion.
KR100507771B1 (ko) * 2002-11-08 2005-08-17 한미약품 주식회사 난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
KR20200083657A (ko) 2002-12-09 2020-07-08 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
KR100502821B1 (ko) 2002-12-26 2005-07-22 이호영 구리산화물 또는 구리 나노와이어로 이루어진 전자방출팁의 저온 형성 방법 및 이 방법에 의해 제조된 전자방출팁을 포함하는 디스플레이 장치 또는 광원
JP4777873B2 (ja) 2003-02-14 2011-09-21 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 親油性薬物送達ビヒクルおよびこれらの使用方法
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
WO2004091506A2 (en) * 2003-04-10 2004-10-28 Ivax Research, Inc. Taxane-based compositions and methods of use
DE602004009681T2 (de) * 2003-05-16 2008-08-14 Velocys, Inc., Plain City Verfahren zur erzeugung einer emulsion durch verwendung einer mikrokanalverfahrentechnologie
US7485671B2 (en) * 2003-05-16 2009-02-03 Velocys, Inc. Process for forming an emulsion using microchannel process technology
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
EP1498120A1 (de) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Halbfeste Formulierung für die orale Verabreichung des Taxols
EP1510206A1 (de) * 2003-08-29 2005-03-02 Novagali Pharma SA Selbstnanoemulgierende ölige Formulierung zur Verabreichung wasserschwerlöslicher Wirkstoffe
US20060292186A1 (en) * 2003-08-29 2006-12-28 Novagali Pharma Sa Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
US20050107465A1 (en) * 2003-10-01 2005-05-19 Papas Andreas M. Composition for treating inflammatory bowel disease
US20050074446A1 (en) * 2003-10-01 2005-04-07 Papas Andreas M. Gamma-tocopherol treatment for cystic fibrosis
CN100471886C (zh) * 2003-10-10 2009-03-25 株式会社三养社 两亲嵌段共聚物以及包含它的用于给药的聚合组合物
EP1670838B1 (de) * 2003-10-10 2015-12-09 Samyang Biopharmaceuticals Corporation Amphiphiles blockcopolymer und dieses enthaltende polymerzusammensetzung für die arzneistoffzufuhr
US7311901B2 (en) * 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
US20080045559A1 (en) * 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
JP2007509978A (ja) * 2003-10-29 2007-04-19 ソーナス ファーマシューティカルズ， インコーポレイテッド トコフェロール修飾治療薬化合物
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
TWI350183B (en) * 2003-12-31 2011-10-11 Ind Tech Res Inst A liposome and a preparation method
US20050158329A1 (en) * 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
WO2005084678A1 (en) * 2004-03-03 2005-09-15 Vital Health Sciences Pty Ltd Alkaloid formulations
US20050209315A1 (en) * 2004-03-20 2005-09-22 Papas Andreas M Bioavailable nutritional supplement and method of treatment of malabsorption
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US20050220866A1 (en) * 2004-04-02 2005-10-06 Dr. Reddy's Laboratories Limited Novel capsule formulations of etoposide for oral use
US20050226932A1 (en) * 2004-04-09 2005-10-13 Samyang Corporation Pharmaceutical formulations for itraconazole
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
KR100582604B1 (ko) 2004-06-16 2006-05-23 보람제약주식회사 항산화제를 포함한 이부프로펜 및 덱시부프로펜의마이크로 에멀젼과 이를 이용한 투명 액제 및 투명연질캡슐 제제
EP1778217A4 (de) * 2004-07-28 2008-10-08 Sd Pharmaceuticals Inc Stabile injizierbare zusammensetzung von alpha-tocopherylsuccinat; analoga und salze davon"
KR101238703B1 (ko) * 2004-08-03 2013-03-04 바이탈 헬스 사이언시즈 피티와이 리미티드 경구 투여용 담체
KR100623013B1 (ko) * 2004-09-04 2006-09-19 김영대 나노에멀션, 그의 용도 및 제조방법
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US20060165769A1 (en) * 2004-09-30 2006-07-27 Hyatt John A Pharmaceutical formulations containing vitamin E TPGS molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
JP5643474B2 (ja) * 2004-10-01 2014-12-17 ヴェロシス，インク． マイクロチャネルプロセス技術を用いる多相混合プロセス
WO2006047579A2 (en) * 2004-10-26 2006-05-04 Yasoo Health, Inc. Vitamin e tpgs fluid concentrate comprising a low percentage of water
CN102580593A (zh) * 2004-11-17 2012-07-18 万罗赛斯公司 使用微通道处理技术的乳化方法
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
JP4877899B2 (ja) * 2005-01-25 2012-02-15 学校法人近畿大学 薬物徐放出性球状微粒子及びその製造方法
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
US20060222716A1 (en) * 2005-04-01 2006-10-05 Joseph Schwarz Colloidal solid lipid vehicle for pharmaceutical use
WO2006110862A2 (en) * 2005-04-12 2006-10-19 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
US20060240051A1 (en) * 2005-04-26 2006-10-26 Singleton Andy H Eutectic blends containing a water soluble vitamin derivative
KR20080000682A (ko) 2005-04-29 2008-01-02 코산 바이오사이언시즈, 인코포레이티드 17-ａａｇ 또는 17-ａｇ, 또는 이들의 프로드럭을 사용한다발성 골수종의 치료 방법
JP4866349B2 (ja) * 2005-06-13 2012-02-01 大日本住友製薬株式会社 可溶化型製剤
ES2557475T3 (es) * 2005-06-17 2016-01-26 Vital Health Sciences Pty Ltd. Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones
EP1915145A1 (de) 2005-07-29 2008-04-30 Blanchette Rockefeller Neurosciences Institute Verwendung eines pkc-aktivators, allein oder in kombination mit einem pkc-hemmer zur verbesserung des langzeitgedächtnisses
WO2007021228A1 (en) * 2005-08-12 2007-02-22 Astrazeneca Ab Process
ATE538139T1 (de) * 2005-08-30 2012-01-15 Lanxess Deutschland Gmbh Verwendung von katalysatoren für den metatheseabbau von nitrilkautschuk
US20090306198A1 (en) * 2005-09-16 2009-12-10 Robert Nicolosi Anti-Oxidant Synergy Formulation Nanoemulsions to Treat Caner
WO2007050574A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
WO2007056424A2 (en) * 2005-11-07 2007-05-18 Penwest Pharmaceuticals, Co. Controlled-release emulsion compositions
EP1959966B1 (de) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolon-formulierungen und verfahren zu ihrer herstellung und verwendung
DK1965787T3 (da) * 2005-11-30 2013-06-03 Endo Pharmaceuticals Inc Behandling af xerostomi med en svovlindeholdende antioxidant
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
ES2594368T3 (es) 2005-12-08 2016-12-19 Insmed Incorporated Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
KR101872061B1 (ko) 2005-12-19 2018-06-27 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이 조성물의 제조 방법 및 그 조성물의 이용 방법
CN101011355B (zh) * 2006-02-01 2013-01-02 陈献 经维生素e琥珀酸酯稳定的医药组合物、其制备及用途
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
BRPI0708773B1 (pt) * 2006-03-10 2021-10-19 Laboswiss Ag Método para solubilização, dispersão e estabilização de substâncias, produtos manufaturados de acordo com o método, bem como uso dos mesmos
US8048383B2 (en) 2006-04-20 2011-11-01 Velocys, Inc. Process for treating and/or forming a non-Newtonian fluid using microchannel process technology
US8112292B2 (en) 2006-04-21 2012-02-07 Medtronic Navigation, Inc. Method and apparatus for optimizing a therapy
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
EP2532235A1 (de) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Hemmer der Bruton-Tyrosinkinase
US8660635B2 (en) 2006-09-29 2014-02-25 Medtronic, Inc. Method and apparatus for optimizing a computer assisted surgical procedure
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
EP2241342A3 (de) * 2006-11-20 2011-01-12 Lutonix, Inc. Wirkstofffreisetzende Beschichtungen für medizinische Vorrichtungen
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
JP2010510988A (ja) 2006-11-28 2010-04-08 マリナス ファーマシューティカルズ ナノ粒子製剤とその製造方法およびその利用
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
WO2008088037A1 (ja) * 2007-01-18 2008-07-24 National University Corporation Chiba University 微粒子製剤
WO2008097165A1 (en) * 2007-02-09 2008-08-14 Astrazeneca Ab Process for preparation of a stable dispersion of solid amorphous submicron particles in an aqueous medium
EP3332797A3 (de) * 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutische wirkungen von bryostatinen, bryologen und anderen damit zusammenhängenden substanzen auf durch kopftraumata herbeigeführte gedächtnisstörungen und hirnverletzungen
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
US20080227805A1 (en) * 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
AU2008269179A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without Tween 80
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
JP5411141B2 (ja) 2007-09-10 2014-02-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
AU2008310956B2 (en) * 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20090130198A1 (en) 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
EA016434B1 (ru) * 2007-12-24 2012-04-30 Сан Фарма Адвансед Ресёрч Компани Лимитед Нанодисперсия
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CN101519404B (zh) 2008-02-29 2016-01-20 唐莉 15环噻酮衍生物及其制备方法与应用
US8765661B2 (en) 2008-03-20 2014-07-01 Virun, Inc. Compositions containing non-polar compounds
DE102008015366A1 (de) * 2008-03-20 2009-09-24 Merck Patent Gmbh Lyophilisierte Nanoemulsion
WO2009117152A1 (en) 2008-03-20 2009-09-24 Virun, Inc. Emulsions including a peg-derivative of tocopherol
CN101998828A (zh) * 2008-03-28 2011-03-30 粒子科学有限公司 用于使治疗剂增溶的药物溶液和方法
US8420110B2 (en) * 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
WO2009148698A1 (en) 2008-06-02 2009-12-10 Cedars-Sinai Medical Center Nanometer-sized prodrugs of nsaids
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
WO2010009075A1 (en) * 2008-07-14 2010-01-21 The University Of North Carolina At Chapel Hill Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds
FR2933871B1 (fr) * 2008-07-18 2012-12-14 Yvery Formulation destinee a ameliorer la biodisponibilite d'une molecule hydrophobe
WO2010027875A2 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9676744B2 (en) 2008-09-19 2017-06-13 Purdue Research Foundation Long-chain carboxychromanols and analogs for use as anti-inflammatory agents
WO2010033687A1 (en) * 2008-09-19 2010-03-25 Purdue Research Foundation Long-chain carboxychromanols and analogs for use as anti-inflammatory agents
US8165658B2 (en) * 2008-09-26 2012-04-24 Medtronic, Inc. Method and apparatus for positioning a guide relative to a base
US20140105822A1 (en) * 2008-11-24 2014-04-17 Cedars-Sinai Medical Center Nanospheres comprising tocopherol, an amphiphilic spacer and a therapeutic or imaging agent
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JP5339980B2 (ja) * 2009-03-23 2013-11-13 富士フイルム株式会社 分散組成物及び分散組成物の製造方法
US9017725B2 (en) * 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
AU2010261342A1 (en) 2009-06-19 2012-01-19 Sun Pharma Advanced Research Company Ltd., Nanodispersion of a drug and process for its preparation
US20110081293A1 (en) * 2009-10-07 2011-04-07 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding lipid compounds
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
CN102101863B (zh) 2009-12-17 2014-10-15 唐莉 新型环氧噻酮化合物及其制备方法和用途
US20110166214A1 (en) 2010-01-07 2011-07-07 Innopharma, Llc Methods and compositions for delivery of taxanes in stable oil-in-water emulsions
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
CN103037708B (zh) * 2010-03-23 2015-05-20 维尔恩公司 含有蔗糖脂肪酸酯的纳米乳液
JP5837919B2 (ja) 2010-03-26 2015-12-24 オンコノバ・セラピューティックス・インコーポレーテッド （ｅ）−４−カルボキシスチリル−４−クロロベンジルスルホンの改善された安定な水性製剤
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
PL2563776T3 (pl) 2010-04-27 2017-01-31 Calcimedica Inc Związki, które modulują wewnątrzkomórkowy wapń
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2566474B1 (de) 2010-05-03 2017-11-15 Teikoku Pharma USA, Inc. Nichtwässrige taxan-pro-emulsionsformulierungen sowie verfahren zu ihrer herstellung und verwendung
ES2688072T3 (es) 2010-05-11 2018-10-30 Mallinckrodt Ard Ip Limited ACTH para el tratamiento de la esclerosis lateral amiotrófica
US20130172333A1 (en) * 2010-05-20 2013-07-04 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
CN103180316A (zh) 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
EP2637655B1 (de) * 2010-11-08 2019-01-09 Cadila Pharmaceuticals Ltd. Pharmazeutische zusammensetzung von taxoiden
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
ES2981782T3 (es) * 2011-02-04 2024-10-10 Infirst Healthcare Ltd Composiciones y métodos para tratar la inflamación crónica y enfermedades inflamatorias
EP2685992A4 (de) 2011-03-15 2014-09-10 Phosphagenics Ltd Aminochinoline als kinasehemmer
CA2853806C (en) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
US9717678B2 (en) * 2011-11-06 2017-08-01 Murty Pharmaceuticals, Inc. Delivery systems for improving oral bioavailability of Fenobam, its hydrates, and salts
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
SG11201404640YA (en) 2012-02-10 2014-09-26 Virun Inc Beverage compositions containing non-polar compounds
US20130226550A1 (en) * 2012-02-23 2013-08-29 Hassan Benameur Systems and methods for modeling compound formulations
HRP20220158T1 (hr) 2012-05-21 2022-04-15 Insmed Incorporated Sustavi za liječenje plućnih infekcija
AR091857A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
AR091858A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN104884047A (zh) 2012-11-29 2015-09-02 英斯梅德股份有限公司 稳定的万古霉素制剂
CN104955446B (zh) * 2012-12-21 2017-08-22 财团法人卫生研究院 用于吸收油脂的中孔洞硅奈米粒子
JP6122646B2 (ja) * 2013-01-23 2017-04-26 昭和電工株式会社 皮膚外用剤
EP2968475A2 (de) 2013-03-14 2016-01-20 Questcor Pharmaceuticals, Inc. Acth zur behandlung des akuten atemstresssyndroms
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
WO2014165672A1 (en) * 2013-04-06 2014-10-09 Igdrasol, Inc. Nanoparticle therapeutic agents, their formulations, and methods of their use
US9585417B2 (en) * 2013-06-20 2017-03-07 Vitasome Labs, Inc. Dietary supplement compositions with enhanced delivery matrix, and methods of making the same
US10299492B2 (en) * 2013-06-20 2019-05-28 James John YIANNIOS Dietary supplement compositions with enhanced delivery matrix, gummies, chocolates, atomizers and powders containing same, and methods of making same
US11044923B2 (en) 2013-06-20 2021-06-29 Vitasome Labs, Inc. Gummies containing formulations with enhanced delivery matrix, and methods of making same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
US9896403B2 (en) * 2014-08-22 2018-02-20 Ironstone Separations, Inc. Solubilization of pterostilbene and resveratrol in aqueous beverages
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6345786B2 (ja) 2013-12-05 2018-06-20 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
CA2949078C (en) 2014-05-15 2022-09-20 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
MY182652A (en) * 2014-11-25 2021-01-27 Kl Kepong Oleomas Sdn Bhd Formulation for effective tocotrienol delivery
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
BR112017018316A2 (pt) 2015-02-27 2018-04-17 Ebbu Llc composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
US20180098936A1 (en) * 2015-03-23 2018-04-12 President And Fellows Of Harvard College Methods and compositions for injecting high concentration and/or high viscosity active agent solutions
CN108135904A (zh) 2015-08-31 2018-06-08 药品循环有限责任公司 用于治疗多发性骨髓瘤的btk抑制剂组合
TWI838700B (zh) 2015-09-30 2024-04-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
WO2017074957A1 (en) 2015-10-26 2017-05-04 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
WO2017119928A1 (en) 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long acting injectable formulations
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
WO2017176652A2 (en) 2016-04-04 2017-10-12 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
JP2019516700A (ja) 2016-05-12 2019-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
EP3463576A4 (de) 2016-05-25 2020-01-15 Concentric Analgesics, Inc. Prodrugs von phenolischen trpv1-agonisten in kombination mit lokalanästhetika und vasokonstriktoren für verbesserte lokalanästhesie
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
AU2017314842B9 (en) 2016-08-26 2022-02-10 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
EP3503875A4 (de) 2016-08-29 2020-06-24 Canopy Growth Corporation Wasserlösliche zusammensetzungen mit gereinigten cannabinoiden
EP3541358A1 (de) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermale verabreichung von grossen wirkstoffen
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
CN110662733A (zh) 2016-12-21 2020-01-07 埃维科生物技术有限公司 方法
WO2018129345A1 (en) 2017-01-08 2018-07-12 Resq Pharma, Inc. Methods for decreasing injuries associated with intraoperative hypotension
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
CN112739345A (zh) 2017-11-06 2021-04-30 斯奈普生物公司 Pim激酶抑制剂组合物，方法和其用途
US10632209B2 (en) 2017-11-10 2020-04-28 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
JP7414282B2 (ja) 2017-12-07 2024-01-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｎｓｄファミリー阻害物質及びそれによる治療の方法
EP3508562A1 (de) * 2018-01-05 2019-07-10 Castrol Limited Mizellare emulsionen
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
EP3773505A4 (de) 2018-03-30 2021-12-22 Insmed Incorporated Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
WO2019212899A1 (en) 2018-04-30 2019-11-07 Cedars-Sinai Medical Center Methods and systems for selection and treatment of patients with inflammatory diseases
EP3810138A4 (de) * 2018-05-25 2022-03-09 RESQ Pharma Inc. Lipidemulsionen und verwendungen davon
WO2019236957A1 (en) 2018-06-07 2019-12-12 The Regents Of The University Of Michigan Prc1 inhibitors and methods of treatment therewith
JP2021532183A (ja) 2018-07-27 2021-11-25 コンセントリック アナルジェジクス，インク． フェノール性ｔｒｐｖ１アゴニストのｐｅｇ化プロドラッグ
WO2020046466A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology, Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
US20220040201A1 (en) * 2018-09-25 2022-02-10 Tolmar International, Ltd. Liquid polymer delivery system for extended administration of drugs
US20200108102A1 (en) 2018-10-03 2020-04-09 Myos Rens Technology Inc. Spray dried follistatin product
WO2020096660A1 (en) 2018-11-06 2020-05-14 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
WO2020135920A1 (en) * 2018-12-28 2020-07-02 Université Libre de Bruxelles Kit for inhaled chemotherapy, and treatment of lung cancer with said kit
KR20210117261A (ko) 2018-12-31 2021-09-28 바이오메아 퓨전, 인크. 메닌-mll 상호작용의 비가역적 억제제
WO2020160113A1 (en) 2019-02-01 2020-08-06 Myos Rens Technology Inc. Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals
CA3133093A1 (en) 2019-03-15 2020-09-24 Unicycive Therapeutics, Inc. Nicorandil derivatives
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
EP3986429A4 (de) 2019-06-21 2023-07-19 Entelexo Biotherapeutics Inc. Plattformen, zusammensetzungen und verfahren zur verabreichung von therapeutika
WO2021195260A1 (en) 2020-03-25 2021-09-30 Forge Therapeutics, Inc. Lpxc inhibitor and methods of making
US20210315902A1 (en) * 2020-03-25 2021-10-14 Forge Therapeutics, Inc. Lpxc inhibitor, formulations, and uses thereof
US11717490B2 (en) * 2020-06-05 2023-08-08 University Of Cyprus Therapeutic nanocarrier system and methods of use
US11858925B2 (en) 2020-07-10 2024-01-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof
JP2023543352A (ja) * 2020-09-22 2023-10-13 マイクロナイゼーション テクノロジーズ アンド セラピューティクス グループ エルエルシー 噴霧器および噴霧化された抗ウイルス薬
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2024086613A2 (en) 2022-10-19 2024-04-25 Myos Corp. Myogenic compounds

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
US4551332A (en) 1981-08-05 1985-11-05 Theodore Stillman Vitamin E compositions and methods
US4578391A (en) 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
US4439432A (en) 1982-03-22 1984-03-27 Peat Raymond F Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols
FR2581310B1 (fr) 1985-05-02 1988-09-23 Natura Medica Laboratoires Composition therapeutique comportant de l'acide a-linolenique et un compose susceptible de favoriser le passage de l'acide au travers de la membrane cellulaire et extrait de plantes comprenant l'acide et le compose
US4784845A (en) 1985-09-16 1988-11-15 American Cyanamid Company Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs
US5041278A (en) 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US4797285A (en) 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
US4898735A (en) 1985-12-06 1990-02-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Liposome/doxorubicin composition and method
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
FI883337A (fi) 1987-07-16 1989-01-17 Bristol Myers Co Icke-vattenloesningar av doxorubicinhydroklorin.
US4997852A (en) * 1987-08-26 1991-03-05 Ohio State University Research Foundation Method and composition for achieving cancer chemopreventive and chemotherapeutic activity
AU620048B2 (en) 1987-09-03 1992-02-13 University Of Georgia Research Foundation, Inc., The Ocular cyclosporin composition
DE3883246T2 (de) 1987-10-19 1993-12-02 Liposome Co Inc Auf tocopherol basierte arzneimittelsysteme.
US4960814A (en) 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
FR2641832B1 (fr) * 1989-01-13 1991-04-12 Melchior Jean Accouplement pour la transmission de couples alternes
US5532002A (en) 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
US5169846A (en) 1989-10-12 1992-12-08 Crooks Michael J Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
FR2657526B1 (fr) 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
AU653325B2 (en) 1990-02-12 1994-09-29 Lucky Limited A composition durably releasing bioactive polypeptides
DK0474647T3 (da) 1990-03-28 1997-08-18 Noven Pharma Fremgangsmåde og indretning til frigivelse af lægemidler til huden
US5114957A (en) 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5179122A (en) 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US6150398A (en) * 1991-05-08 2000-11-21 The United States Of America As Represented By The Department Of Health And Human Services Methods for the treatment of cancer
US5391337A (en) * 1991-06-24 1995-02-21 Ford Motor Company Method for making evaporative casting patterns
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
EP0546951A1 (de) 1991-12-13 1993-06-16 The Liposome Company, Inc. Kombination von im Liposomen verkapselten antineoplastischen Mitteln wie Doxorubicin, mit Kolonie-stimulierenden Faktoren
SE9200951D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US6153193A (en) 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
GB9224502D0 (en) 1992-11-23 1993-01-13 New Roger R C Method of preparing a lipid-containing formulation
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1994020143A1 (en) 1993-03-03 1994-09-15 Fujisawa Pharmaceutical Co., Ltd. Optical isomerization inhibitor
CA2092271C (en) * 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
WO1994026254A1 (en) 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
DE4322826A1 (de) 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5468769A (en) * 1993-07-15 1995-11-21 Abbott Laboratories Paclitaxel derivatives
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
ES2148345T3 (es) 1993-10-22 2000-10-16 Hexal Ag Composicion farmaceutica con ciclosporina a, un derivado de vitamina e y un emulsionante.
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
JPH09507233A (ja) 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
US5731334A (en) * 1994-01-11 1998-03-24 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
CZ285795B6 (cs) 1994-02-04 1999-11-17 Scotia Lipidteknik Ab Emulse oleje ve vodě, její použití a farmaceutický prostředek, který ji obsahuje
AU709783B2 (en) 1994-03-14 1999-09-09 Abbott Laboratories Aerosol drug formulations containing vitamin E
JP4157969B2 (ja) * 1994-03-18 2008-10-01 スパーナス ファーマシューティカルズ インコーポレイテッド 乳化薬物送達システム
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
DE4432378A1 (de) 1994-09-12 1996-03-14 Bayer Ag Injizierbare liposomale Arzneizubereitungen
WO1996015774A1 (en) 1994-11-18 1996-05-30 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
HU215966B (hu) 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
GB9424901D0 (en) 1994-12-09 1995-02-08 Cortecs Ltd Sequestration Agents
GB9424902D0 (en) 1994-12-09 1995-02-08 Cortecs Ltd Solubilisation Aids
GB9424908D0 (en) 1994-12-09 1995-02-08 Cortecs Ltd Anti-Oxidant Compositions
CA2146098A1 (en) * 1995-01-12 1996-07-13 Ray V. Rajotte Bulk cryopreservation of biological materials and uses for cryopreserved and encapsulated biological materials
KR100239799B1 (ko) 1995-01-21 2000-02-01 손경식 경구투여용 사이클로스포린 에이 고체미셀분산체, 이의 제조 방법 및 고형제제
US5681846A (en) 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US5616342A (en) 1995-04-11 1997-04-01 Pdt, Inc. Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof
JPH11504028A (ja) 1995-04-24 1999-04-06 イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム 油／水エマルジョンを作り出す自己乳化性配合物
WO1996033987A1 (en) 1995-04-26 1996-10-31 Henkel Corporation Method of producing a tocopherol product
DK0826688T3 (da) * 1995-04-28 2001-10-22 Daiichi Seiyaku Co Pentacykliske forbindelser
EP0825849A1 (de) * 1995-05-19 1998-03-04 Abbott Laboratories Selbstemulgierbare arzneiformulierungen für lipophile arzneimittel
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
GB9514878D0 (en) 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
US5504220A (en) 1995-08-17 1996-04-02 Eastman Chemical Company Preparation of α-tocopherol
SE9503143D0 (sv) 1995-09-12 1995-09-12 Astra Ab New preparation
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
WO1997013528A1 (en) 1995-10-12 1997-04-17 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
US5965750A (en) 1995-10-17 1999-10-12 Showa Denko K.K. High- purity tocopherol phosphates, process for the preparation thereof, methods for analysis thereof, and cosmetics
US5733526A (en) * 1995-12-14 1998-03-31 Alliance Pharmaceutical Corp. Hydrocarbon oil/fluorochemical preparations and methods of use
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
DE19547986C1 (de) 1995-12-21 1997-07-10 Henkel Kgaa O/W-Mikroemulsionen
RU2160258C2 (ru) 1996-01-29 2000-12-10 Басф Акциенгезелльшафт СПОСОБ ПОЛУЧЕНИЯ DL-α-ТОКОФЕРОЛА ИЛИ DL-α-ТОКОФЕРИЛАЦЕТАТА
AU1671197A (en) 1996-02-13 1997-09-02 Nisshin Oil Mills, Ltd., The Vaccine-containing emulsion and vaccine-containing powder for oral administration and process for producing the same
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
SI0932399T1 (sl) 1996-03-12 2006-10-31 Pg Txl Co Lp Vodotopna paklitakselna predzdravila
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
JP4142742B2 (ja) 1996-05-23 2008-09-03 大正製薬株式会社 マイクロエマルション
WO1997046204A2 (en) 1996-06-05 1997-12-11 Ashmont Holdings Limited Injectable compositions
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
AU727447B2 (en) 1996-07-03 2000-12-14 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
US5744062A (en) 1996-08-29 1998-04-28 R.I.T.A. Corporation Balanced emulsifier blends for oil-in-water emulsions
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
PT937090E (pt) 1996-10-08 2002-12-31 Kreatech Biotech Bv Metodos para a marcacao de nucleotidos, nucleotidos marcados e intermediarios uteis
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
CA2189916C (en) * 1996-11-08 2001-01-16 Parkash S. Gill A new regime for paclitaxel in kaposi's sarcoma patients
US5908939A (en) 1996-11-11 1999-06-01 Roche Vitamins Inc. Method of making D,L-A-tocopherol
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
WO1998040094A1 (en) 1997-03-12 1998-09-17 Abbott Laboratories Hydrophilic binary systems for the administration of cyclosporine
US6537561B1 (en) 1997-02-27 2003-03-25 Nippon Shinyaku Co., Ltd. Fat emulsion for oral administration
JP2001515491A (ja) 1997-03-12 2001-09-18 アボツト・ラボラトリーズ 親油性化合物の投与のための親油性二成分系
EP0988858A1 (de) 1997-04-18 2000-03-29 Taisho Pharmaceutical Co., Ltd Mikroemulsion
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
WO2001025223A1 (en) * 1999-10-06 2001-04-12 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel

Also Published As

Publication number Publication date
TW200425913A (en) 2004-12-01
KR20000069893A (ko) 2000-11-25
US20040202712A1 (en) 2004-10-14
US6982282B2 (en) 2006-01-03
AR011518A1 (es) 2000-08-30
US20030147959A1 (en) 2003-08-07
ES2285753T3 (es) 2007-11-16
EP0981328A1 (de) 2000-03-01
US20030109575A1 (en) 2003-06-12
US20030170279A1 (en) 2003-09-11
DK0981328T3 (da) 2007-07-02
DE69837328D1 (de) 2007-04-26
EP0981328B1 (de) 2007-03-14
US20050142189A1 (en) 2005-06-30
WO1998030205A1 (en) 1998-07-16
KR100612528B1 (ko) 2006-08-11
TW579297B (en) 2004-03-11
IL130737A0 (en) 2000-06-01
CA2276730A1 (en) 1998-07-16
JP2007332157A (ja) 2007-12-27
US20030027858A1 (en) 2003-02-06
ATE356611T1 (de) 2007-04-15
US20030104015A1 (en) 2003-06-05
US6667048B1 (en) 2003-12-23
JP2001508445A (ja) 2001-06-26
DE69837328T2 (de) 2007-12-20
US6660286B1 (en) 2003-12-09
PT981328E (pt) 2007-05-31
CA2276730C (en) 2004-10-26
US6458373B1 (en) 2002-10-01

Similar Documents

Publication Publication Date Title
BE2018C032I2 (de)
IN183539B (de)
IN189614B (de)
CH0944937H2 (de)
ITMI971440A0 (de)
ITUD970058A0 (de)
BE2013C047I2 (de)
BR9701757A (de)
ITME970005V0 (de)
ITGE970008V0 (de)
IN187641B (de)
IN184313B (de)
ECSDI970460S (de)
ITRM970371A0 (de)
ITRM970311A0 (de)
IN192031B (de)
BR9700653A (de)
CN3058000S (de)
CN3057436S (de)
CN3058320S (de)
CN3058269S (de)
CN3058162S (de)
CN3058462S (de)
CN3058531S (de)
CN3056875S (de)